Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment

Completed · Phase 1

Conditions studied: Hepatitis C

In brief

The purpose of this study is to assess the effect of renal function impairment on the single dose pharmacokinetics of Daclatasvir.

Key facts

Study ID

NCT01830205

Run by

Bristol-Myers Squibb

People needed

58

Starts

2012-09-01

Expected to finish

2013-06-01

Last updated by the study team

2015-11-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Meet renal function criteria in one of four categories

You may not qualify if…

• Unstable or uncontrolled medical conditions

Where it is running

• Orlando Clinical Research Center — Orlando, Florida, United States
• Davita Clinical Research — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.